ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1748

Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis

Sung Cheol Jung1, Jeffrey Curtis2, Seojin Yang3, Min Hyuk Lim4, Saram Lee5, Sung Ik Cho6, Jin Kyun Park7 and Eun Bong Lee6, 1Seoul National University College of Medicine, Seoul, Republic of Korea, 2University of Alabama at Birmingham, Birmingham, AL, 3Seoul National University, Seoul, Republic of Korea, 4Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea, 5Seoul National University Hospital, Seoul, Republic of Korea, 6Seoul National University Hospital, Seoul, South Korea, 7Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea

Meeting: ACR Convergence 2025

Keywords: Environmental factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: While air pollution has been implicated in the pathogenesis of rheumatoid arthritis (RA), its association with RA disease activity remains insufficiently investigated (1, 2). We aimed to evaluate the effect of air pollution on disease activity and flare occurrence in patients with RA.

Methods: This prospective study included patients with RA who visited a tertiary medical center in South Korea between January 2021 and October 2024, with at least 6 months of follow-up. Air pollution levels were assessed using monthly mean concentrations of six air pollutants (SO2, NO2, O3, CO, PM10, and PM2.5) obtained from the Korean National Institute of Environmental. RA disease activity was evaluated using the tender joint count, swollen joint count based on 28 joints (TJC28, SJC28), clinical disease activity Index (CDAI), and disease activity score based on 28 joints (DAS28). Flare events were defined based increases in DAS28 scores. Associations between air pollution and RA disease activity or flare occurrence were analyzed using linear and logistic generalized estimating equations (GEE), accounting for repeated measures within the study population and adjusting for prespecified covariates including age, sex, smoking status, serologic status, dose of concomitant glucocorticoids, type of disease-modifying anti-rheumatic drugs (DMARDs), and climate variables (temperature and humidity).

Results: A total of 1,056 RA patients were included, with a mean (SD) age of 61.2 (12.7) years, and 907 (85.9%) were female. Patients contributed data for a median (IQR) of 11.0 (8.0, 13.0) visits. There were 1,724 flare events during the observation period, with an incidence rate of 56.3 per 100 person-years (95% CI: 53.7 to 59.1). Air pollution concentrations were high in winter and spring and low in summer (Figure 1). Increases in PM10, and PM2.5 levels were associated with flare occurrence (Table 1). Among individual pollutants, O3 was associated with SJC28 and CDAI, and PM10 was associated with both DAS28 CRP and DAS28 ESR. In particular, higher PM 2.5 levels showed the strongest association with increased RA disease activity, with β coefficients (95% CIs) of 0.078 (0.020 to 0.136) for TJC28, 0.068 (0.023 to 0.112) for SJC28, 0.211 (0.069 to 0.353) for CDAI, 0.040 (0.017 to 0.064) for DAS28 CRP, 0.037 (0.013 to 0.061) for DAS28 ESR when six air pollutants were standardized to a mean of 0 and standard deviation of 1 (Table 2).

Conclusion: Elevated air pollution levels, especially PM 2.5, are associated with increased RA disease activity and flare occurrence in patients of RA.References1. Zhang RD, Chen C, Wang P, Fang Y, Jiang LQ, Fang X, et al. Air pollution exposure and auto-inflammatory and autoimmune diseases of the musculoskeletal system: a review of epidemiologic and mechanistic evidence. Environ Geochem Health. 2023;45(7):4087-105.2. Ingegnoli F, Ubiali T, Schioppo T, Longo V, Murgo A, De Lucia O, et al. Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study. Int J Environ Res Public Health. 2021;18(16).

Supporting image 1Figure 1. Longitudinal trends of monthly Air Pollutant concentrations

Supporting image 2Table 1. Effects of Air Pollution on Flare occurrence in RA

Supporting image 3Table 2. Effects of Air Pollution on Disease Activity in RA


Disclosures: S. Jung: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bendcare, 5, Bristol-Myers Squibb(BMS), 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, FASTER, 2, 4, Genentech, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Moderna, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sanofi, 2, 5, UCB, 2, 5; S. Yang: None; M. Lim: None; S. Lee: None; S. Cho: None; J. Park: None; E. Lee: None.

To cite this abstract in AMA style:

Jung S, Curtis J, Yang S, Lim M, Lee S, Cho S, Park J, Lee E. Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effect-of-air-pollution-on-disease-activity-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-air-pollution-on-disease-activity-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology